Ignace Vergote
Ignace Vergote
Professor of Gynecologic Oncology, University of Leuven
Verified email at uzleuven.be
Title
Cited by
Cited by
Year
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
I Vergote, CG Tropé, F Amant, GB Kristensen, T Ehlen, N Johnson, ...
New England Journal of Medicine 363 (10), 943-953, 2010
17472010
Endometrial cancer
F Amant, P Moerman, P Neven, D Timmerman, E Van Limbergen, ...
The Lancet 366 (9484), 491-505, 2005
15312005
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
New England Journal of Medicine 366 (15), 1382-1392, 2012
13522012
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised …
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
The lancet oncology 15 (8), 852-861, 2014
11442014
Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
MJ Piccart, K Bertelsen, K James, J Cassidy, C Mangioni, E Simonsen, ...
Journal of the National Cancer Institute 92 (9), 699-708, 2000
11412000
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ...
New England Journal of Medicine 375 (22), 2154-2164, 2016
10882016
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and …
J Bonneterre, B Thürlimann, JFR Robertson, M Krzakowski, L Mauriac, ...
Journal of clinical oncology 18 (22), 3748-3757, 2000
10272000
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial
E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ...
Obstetrical & Gynecological Survey 69 (7), 402-404, 2014
10002014
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with …
MS Aapro, J Bohlius, DA Cameron, L Dal Lago, JP Donnelly, N Kearney, ...
European journal of cancer 47 (1), 8-32, 2011
9122011
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
A Howell, JFR Robertson, J Quaresma Albano, A Aschermannova, ...
Journal of Clinical Oncology 20 (16), 3396-3403, 2002
7842002
Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group
D Timmerman, L Valentin, TH Bourne, WP Collins, H Verrelst, I Vergote
Ultrasound in Obstetrics and Gynecology: The Official Journal of the …, 2000
7012000
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the …
J Pfisterer, M Plante, I Vergote, A du Bois, H Hirte, AJ Lacave, U Wagner, ...
Journal of Clinical Oncology 24 (29), 4699-4707, 2006
6972006
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
I Vergote, J De Brabanter, A Fyles, K Bertelsen, N Einhorn, P Sevelda, ...
The lancet 357 (9251), 176-182, 2001
6842001
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer.
AG Van der Zee, MH Oonk, JA De Hullu, AC Ansink, I Vergote, ...
6742008
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised …
E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ...
The lancet oncology 18 (9), 1274-1284, 2017
6252017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
5442017
Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
E Pujade-Lauraine, U Wagner, E Aavall-Lundqvist, V Gebski, M Heywood, ...
Springer Healthcare, 2013
5432013
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy In …
JB Trimbos, I Vergote, G Bolis, JB Vermorken, C Mangioni, C Madronal, ...
Journal of the National Cancer Institute 95 (2), 113-125, 2003
5272003
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ...
Nature genetics 45 (4), 371-384, 2013
5032013
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin …
SB Kaye, J Lubinski, U Matulonis, JE Ang, C Gourley, BY Karlan, ...
Journal of clinical oncology 30 (4), 372-379, 2012
4712012
The system can't perform the operation now. Try again later.
Articles 1–20